Results 131 to 140 of about 19,887 (159)

Emergence of plasmid-mediated tigecycline resistance tet(X4) gene in Enterobacterales isolated from wild animals in captivity. [PDF]

Sci One Health
Lei L, Xiong P, Yan Z, Zhang Y, Wu Y, Chen G, Song H, Zhang R.   +7 more
europepmc   +1 more source

The ISVsa3-ORF2-abh-tet(X4) circular intermediate-mediated transmission of tigecycline resistance in Escherichia coli isolates from duck farms. [PDF]

Front Cell Infect Microbiol
Jiang C, Yang J, Xiao G, Xiao N, Hu J, Yang Y, Sun Z, Li Y.   +7 more
europepmc   +1 more source

Emergence of a novel high-level tigecycline resistance gene <i>tet</i>(X6) variant coexisting with <i>tet</i>(X2) and two <i>tet</i>(X) copies in a <i>Sphingobacterium</i> sp. [PDF]

Antimicrob Agents Chemother
Xu Q, Hou J, Schwarz S, Chai J, Lin L, Ma C, Zhu Y, Zhang W.   +7 more
europepmc   +1 more source

[Bacterial resistance and a new antibiotic: tigecycline].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2006
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The emergence of clinical resistance to tigecycline

International Journal of Antimicrobial Agents, 2013
Tigecycline (TIG) exhibits broad-spectrum activity against many Gram-positive and Gram-negative pathogens. However, clinical resistance has emerged recently and has been detected following treatment with TIG. This observation suggests that long-term monotherapy may carry a high risk for TIG resistance.
Yan Sun, Yun Cai, Xu Liu
exaly   +3 more sources

Development mechanism of resistant population post-exposure to tigecycline in tigecycline-heteroresistant Acinetobacter baumannii strain

International Journal of Antimicrobial Agents, 2023
Tigecycline heteroresistance is highly prevalent in Acinetobacter baumannii clinical isolates, reducing the efficacy of tigecycline treatment. This study investigated the population dynamics of A. baumannii with tigecycline heteroresistance to determine the origin of resistance that occurs over time after antibiotic exposure.
Jeongwoo Jo, Wonbeom Park, Dae-Hyuk Kweon, Kwan Soo Ko   +3 more
openaire   +2 more sources

RshA mutations contributing to tigecycline resistance in Mycobacteroides abscessus

Journal of Medical Microbiology, 2022
Tigecycline is an important rescue antibiotic for many bacterial infections. In Mycobacteroides abscessus , tigecycline resistance has been associated with dysregulated stress response caused by aberrations in the interaction of the SigH and RshA factors.
Kar Men Aw, Hien Fuh Ng, Col Lin Lee, Thaw Zin, Yun Fong Ngeow   +4 more
openaire   +2 more sources

Establishing the role of tigecycline in an era of antimicrobial resistance

Expert Review of Anti-infective Therapy, 2008
Tigecycline is a glycylcycline antibacterial agent derived from minocycline with a broad spectrum of activity. Like tetracycline agents, it inhibits bacterial protein synthesis but is able to bind to target sites with higher affinity and overcome tetracycline-resistance mechanisms due to structural modifications.
Jason J, Schafer, Debra A, Goff
openaire   +2 more sources

Tigecycline therapy in pediatric patients with multidrug resistant bacteremia

Enfermedades Infecciosas y Microbiología Clínica, 2020
Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients.In this study the effectiveness and safety of tigecycline in children was
Gulhan, Belgin, Senel, EMRAH, Unal, Sevim, Tezer, Hasan, Demirtas, Gokhan, Gonulal, Deniz, Guney, Dogus, Kanik-Yuksek, Saliha, Ozkaya-Parlakay, Aslinur   +8 more
openaire   +3 more sources

Rapid Development of Acinetobacter baumannii Resistance to Tigecycline

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
A 53‐year‐old woman experienced a multidrug‐resistant (MDR) Acinetobacter baumannii urinary tract infection 5 months after undergoing kidney and liver transplantation. The tigecycline minimum inhibitory concentration (MIC) for her A. baumannii isolate was 1.5 μg/ml; the patient received 2 weeks of therapy with intravenous tigecycline as a 100‐mg ...
Gail E, Reid, Shellee A, Grim, Christine A, Aldeza, William M, Janda, Nina M, Clark   +4 more
openaire   +2 more sources